National Cancer Institute. Cancer Stat Facts: Uterine Cancer. National Institutes of Health; 2024 [accessed october 2024]. Available from: https://seer.cancer.gov/statfacts/html/corp.html.
Barretina-Ginesta MP, Quindós M, Alarcón JD, et al. SEOM-GEICO clinical guidelines on endometrial cancer (2021). Clin Transl Oncol 2022;24(4):625-34.
DOI: 10.1007/s12094-022-02799-7
Concin N, Matias-Guiu X, Vergote I, et al. ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma. Int J Gynecol Cancer 2021;31(1):12-39.
DOI: 10.1136/ijgc-2020-002230
Stelloo E, Bosse T, Nout RA, et al. Refining prognosis and identifying targetable pathways for high-risk endometrial cancer; a TransPORTEC initiative. Mod Pathol 2015;28(6):836-44.
DOI: 10.1038/modpathol.2015.43
Van den Heerik ASVM, Horeweg N, Nout RA, et al. PORTEC-4a: international randomized trial of molecular profile-based adjuvant treatment for women with high-intermediate risk endometrial cancer. Int J Gynecol Cancer 2020;30(12):2002-7.
DOI: 10.1136/ijgc-2020-001929
Talhouk A, McConechy MK, Leung S, et al. Confirmation of ProMisE: A simple, genomics-based clinical classifier for endometrial cancer. Cancer 2017;123(5):802-13.
DOI: 10.1002/cncr.30496
Urick ME, Bell DW. Clinical actionability of molecular targets in endometrial cancer. Nat Rev Cancer 2019;19(9):510-21.
DOI: 10.1038/s41568-019-0177-x
León-Castillo A, De Boer SM, Powell ME, et al. Molecular Classification of the PORTEC-3 Trial for High-Risk Endometrial Cancer: Impact on Prognosis and Benefit From Adjuvant Therapy. J Clin Oncol 2020;38(29):3388-97.
DOI: 10.1200/JCO.20.00549
Oaknin A, Bosse TJ, Creutzberg CL, et al. Endometrial cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol 2022;33(9):860-77.
DOI: 10.1016/j.annonc.2022.05.009
Musacchio L, Boccia SM, Caruso G, et al. Immune Checkpoint Inhibitors: A Promising Choice for Endometrial Cancer Patients? J Clin Med 2020;9(6):1721.
DOI: 10.3390/jcm9061721
Marabelle A, Le DT, Ascierto PA, et al. Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair-Deficient Cancer: Results From the Phase II KEYNOTE-158 Study. J Clin Oncol 2020;38(1):1-10.
DOI: 10.1200/JCO.19.02105
Oaknin A, Tinker AV, Gilbert L, et al. Clinical Activity and Safety of the Anti-Programmed Death 1 Monoclonal Antibody Dostarlimab for Patients with Recurrent or Advanced Mismatch Repair-Deficient Endometrial Cancer: A Nonrandomized Phase 1 Clinical Trial. JAMA Oncol 2020;6(11):1766-72.
DOI: 10.1001/jamaoncol.2020.4515
Makker V, Colombo N, Casado Herráez A, et al. Lenvatinib plus Pembrolizumab for Advanced Endometrial Cancer. N Engl J Med 2022;386(5):437-48.
DOI: 10.1056/NEJMoa2108330
Mirza MR, Chase DM, Slomovitz BM, et al. Dostarlimab for Primary Advanced or Recurrent Endometrial Cancer. N Engl J Med 2023;388(23):2145-58.
DOI: 10.1056/NEJMoa2216334
Eskander RN, Sill MW, Beffa L, et al. Pembrolizumab plus Chemotherapy in Advanced Endometrial Cancer. N Engl J Med 2023;388(23):2159-70.
DOI: 10.1056/NEJMoa2302312
Colombo N, Biagioli E, Harano K, et al. Atezolizumab and chemotherapy for advanced or recurrent endometrial cancer (AtTEnd): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 2024;25(9):1135-46.
DOI: 10.1016/S1470-2045(24)00334-6
Bogani G, Monk BJ, Powell MA, et al. Adding immunotherapy to first-line treatment of advanced and metastatic endometrial cancer. Ann Oncol 2024;35(5):414-28.
DOI: 10.1016/j.annonc.2024.02.006
Pignata S, Marth C, Moore RG, et al. Phase III ENGOT-En9/LEAP-001 study: Lenvatinib + pembrolizumab (LEN/PEMBRO) vs chemotherapy (chemo) as first-line (1L) therapy for advanced or recurrent endometrial cancer. ESMO Open 2024;2059-7029.
DOI: 10.1016/j.esmoop.2024.103539
Van Gorp T, Cibula D, Lv W, et al. ENGOT-en11/GOG-3053/KEYNOTE-B21: a randomised, double-blind, phase III study of pembrolizumab or placebo plus adjuvant chemotherapy with or without radiotherapy in patients with newly diagnosed, high-risk endometrial cancer. Ann Oncol 2024.
DOI: 10.1016/j.annonc.2024.08.2267
Mirza MR, Coleman RL, Hanker L, et al ENGOT-EN6/GOG-3031/nsgo-ruby: a phase 3, randomised, double-blind, multicenter study of dostarlimab + carboplatin-paclitaxel versus placebo + carboplatin-paclitaxel in recurrent or primary advanced endometrial cancer (EC). Int J Gyn Can 2020;30(Suppl.4): A112.
DOI: 10.1136/ijgc-2020-ESGO.197
Westin SN, Moore K, Chon HS, et al. Durvalumab Plus Carboplatin/Paclitaxel Followed by Maintenance Durvalumab With or Without Olaparib as First-Line Treatment for Advanced Endometrial Cancer: The Phase III DUO-E Trial. J Clin Oncol 2024;42(3):283-99.
DOI: 10.1200/JCO.23.02132
Borden L, Dvorak J, Barrett Z, et al. MLH1 hypermethylation predicts poor outcomes with pembrolizumab in recurrent endometrial cancer (087). Gynecologic Oncology 2022;166.
DOI: 10.1016/S0090-8258(22)01312-9
Eskander R et al. Presented at ESMO Meeting 2023, Mansoor Mirza et al. Presented as Poster at ASCO Meeting 2024.
Pavelescu LA, Enache RM, Roşu OA, et al. Predictive Biomarkers and Resistance Mechanisms of Checkpoint Inhibitors in Malignant Solid Tumors. Int J Mol Sci 2024;25(17):9659.
DOI: 10.3390/ijms25179659
Vergote I, Pérez-Fidalgo JA, Hamilton EP, et al. Oral Selinexor as Maintenance Therapy After First-Line Chemotherapy for Advanced or Recurrent Endometrial Cancer. J Clin Oncol 2023;41(35):5400-10.
DOI: 10.1200/JCO.22.02906
Makker V, Pérez-Fidalgo JA, Valabrega G, et al. Long-term follow-up of efficacy and safety of selinexor maintenance treatment in patients with TP53wt advanced or recurrent endometrial cancer: A subgroup analysis of the ENGOT-EN5/GOG-3055/SIENDO study. Gynecol Oncol 2024;185:202-11.
DOI: 10.1016/j.ygyno.2024.05.016
Hashim M, Tizen NMS, Alfian N, et al. A study of HER2 expression in endometrial carcinoma: a single centre experience. Pan Afr Med J 2021;38:200.
DOI: 10.11604/pamj.2021.38.200.19978
Yen TT, Wang TL, Fader AN, et al. Molecular Classification and Emerging Targeted Therapy in Endometrial Cancer. Int J Gynecol Pathol 2020;39(1):26-35.
DOI: 10.1097/PGP.0000000000000585
Swift BE, Gien LT. Incorporating Molecular Diagnostics into Treatment Paradigms for Endometrial Cancer. Curr Treat Options Oncol 2022;23(8):1121-34.
DOI: 10.1007/s11864-022-00993-x
Fader AN, Roque DM, Siegel E, et al. Randomized Phase II Trial of Carboplatin-Paclitaxel Versus Carboplatin-Paclitaxel-Trastuzumab in Uterine Serous Carcinomas That Overexpress Human Epidermal Growth Factor Receptor 2/neu. J Clin Oncol 2018;36(20):2044-51.
DOI: 10.1200/JCO.2017.76.5966
Meric-Bernstam F, Makker V, Oaknin A, et al. Efficacy and Safety of Trastuzumab Deruxtecan in Patients with HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II Trial. J Clin Oncol 2024;42(1):47-58.
DOI: 10.1200/JCO.23.02005
Fucà G, Sabatucci I, Paderno M, et al. The clinical landscape of antibody-drug conjugates in endometrial cancer. Int J Gynecol Cancer 2024;34(11):1795-804.
DOI: 10.1136/ijgc-2024-005607
Santin AD, Corr BR, Spira A, et al. Efficacy and Safety of Sacituzumab Govitecan in Patients with Advanced Solid Tumors (TROPiCS-03): Analysis in Patients with Advanced Endometrial Cancer. J Clin Oncol 2024;42(29):3421-9.
DOI: 10.1200/JCO.23.02767
Criscitiello C, Morganti S, Curigliano G. Antibody-drug conjugates in solid tumors: a look into novel targets. J Hematol Oncol 2021;14(1):20.
DOI: 10.1186/s13045-021-01035-z
Bregar A, Deshpande A, Grange C, et al. Characterization of immune regulatory molecules B7-H4 and PD-L1 in low and high grade endometrial tumors. Gynecol Oncol 2017;145(3):446-52.
DOI: 10.1016/j.ygyno.2017.03.006
Peng Y, Wang Y, Zhou C, et al. PI3K/Akt/mTOR Pathway and Its Role in Cancer Therapeutics: Are We Making Headway? Front Oncol 2022;12:819128
DOI: 10.3389/fonc.2022.819128
Slomovitz BM, Filiaci VL, Walker JL, et al. A randomized phase II trial of everolimus and letrozole or hormonal therapy in women with advanced, persistent or recurrent endometrial carcinoma: A GOG Foundation study. Gynecol Oncol 2022;164(3):481-91.
DOI: 10.1016/j.ygyno.2021.12.031
Guan B, Mao TL, Panuganti PK, et al. Mutation and loss of expression of ARID1A in uterine low-grade endometrioid carcinoma. Am J Surg Pathol 2011;35(5):625-32.
DOI: 10.1097/PAS.0b013e318212782a
Bian X, Gao J, Luo F, et al. PTEN deficiency sensitizes endometrioid endometrial cancer to compound PARP-PI3K inhibition but not PARP inhibition as monotherapy. Oncogene 2018;37(3):341-51.
DOI: 10.1038/onc.2017.326
Ethier JL, Desautels DN, Amir E, et al. Is hormonal therapy effective in advanced endometrial cancer? A systematic review and meta-analysis. Gynecol Oncol 2017;147(1):158-66.
DOI: 10.1016/j.ygyno.2017.07.002
Njoku K, Barr CE, Crosbie EJ. Current and Emerging Prognostic Biomarkers in Endometrial Cancer. Front Oncol 2022;12:890908.
DOI: 10.3389/fonc.2022.890908
Mirza MR, Bjørge L, Marmé F, et al. LBA28 A randomised double-blind placebo-controlled phase II trial of palbociclib combined with letrozole (L) in patients (pts) with oestrogen receptor-positive (ER+) advanced/recurrent endometrial cancer (EC): NSGO-PALEO / ENGOT-EN3 trial. Ann Oncol 2020.
DOI: 10.1016/j.annonc.2020.08.2258
Niloff JM, Klug TL, Schaetzl E, ret al. Elevation of serum CA125 in carcinomas of the fallopian tube, endometrium, and endocervix. Am J Obstet Gynecol 1984;148(8):1057-8.
DOI: 10.1016/S0002-9378(84)90444-7
Jiang T, Huang L, Zhang S. Preoperative serum CA125: a useful marker for surgical management of endometrial cancer. BMC Cancer 2015;15:396.
DOI: 10.1186/s12885-015-1260-7
Abbink K, Zusterzeel PL, Geurts-Moespot AJ, et al. HE4 is superior to CA125 in the detection of recurrent disease in high-risk endometrial cancer patients. Tumour Biol 2018;40(2):1010428318757103.
DOI: 10.1177/1010428318757103
Dai C, Zheng Y, Li Y, et al. Prognostic values of HE4 expression in patients with cancer: a meta-analysis. Cancer Manag Res 2018;10:4491-500.
DOI: 10.2147/CMAR.S178345
Chen Q, Zhang ZH, Wang S, et al. Circulating Cell-Free DNA or Circulating Tumor DNA in the Management of Ovarian and Endometrial Cancer. OncoTargets and Therapy 2019;12:11517-30.
DOI: 10.2147/OTT.S227156
Charo LM, Eskander RN, Okamura R, et al Clinical implications of plasma circulating tumor DNA in gynecologic cancer patients. Mol Oncol 2021;15(1):67-79.
DOI: 10.1002/1878-0261.12791
Moss EL, Gorsia DN, Collins A, et al. Utility of Circulating Tumor DNA for Detection and Monitoring of Endometrial Cancer Recurrence and Progression. Cancers (Basel) 2020;12(8):2231.
DOI: 10.3390/cancers12082231
Baker-Rand H, Kitson SJ. Recent Advances in Endometrial Cancer Prevention, Early Diagnosis and Treatment. Cancers (Basel) 2024;16(5):1028.
DOI: 10.3390/cancers16051028
Número de descargas:
1179
Número de visitas:
95
Citas:
0
